Rayzebio Inc's Competitiveness
A competitive positioning analysis and financial ratio benchmarking of Rayzebio Inc (RYZB) against its publicly traded competitors: sales growth, net income, profitability, valuation and market share, plus each peer's market capitalization, revenue, income and employees. Free below: the top 5 peers. Subscriber access adds the full competitor list and CSV downloads.
Peer Data As of Q3 2023
Competitors
179
Peer Group Market Share
-
Revenue Growth Y/Y
-
Net Margin
-
API endpoints for this dataset
https://api.csimarket.com/api/v1/companies/RYZB/competitors
https://api.csimarket.com/api/v1/companies/RYZB/relationships
https://api.csimarket.com/api/v1/companies/RYZB/similar
Programmatic access for models, analytics, and integration workflows.
Explore the Financial Data API
Connect Your AI Assistant
Rayzebio Inc's Competitor Quality Breadth
Group definitions: see Methodology: Performance Group Definitions.
| Entity | Profitable | Expanding | Above Industry Growth | Distressed |
|---|---|---|---|---|
| Rayzebio Inc | - | - | - | Yes |
| Competitors combined (79) | ||||
| High-Confidence Competitors (104) |
Source: CSIMarket API, trailing 12 months. Altman Z-Score is not shown here: it is not populated in the underlying data for any company. Percentages are of companies in each group that report the relevant metric, not of the full group size.
RYZB Stock Performance relative to its Competitors
RYZB
Competitors (weighted)
Percent change over the selected range
RYZB Stock Performance relative to High-Confidence Competitors
RYZB
High-Confidence Competitors (equal-weighted, 108)
Percent change over the selected range
5 Best-Performing Tracked Competitors, Trailing 12 Months
| # | Competitor | TTM Share Price Return | vs U.S.A. 500 |
|---|---|---|---|
| 1 | Adlai Nortye Ltd | 282.9% | Outperformed |
| 2 | Cypherpunk Technologies Inc | 282.9% | Outperformed |
| 3 | 180 Life Sciences Corp | 282.9% | Outperformed |
| 4 | Enliven Therapeutics Inc | 282.9% | Outperformed |
| 5 | Omeros Corporation | 282.9% | Outperformed |
Best-Performing Competitor Returns
TTM share price return and U.S.A. 500 outperformance for Rayzebio Inc's best-performing competitors requires a Commercial License.
Source: CSIMarket API, trailing 12 months.
Publicly Traded Peers of Rayzebio Inc
Revenue and income for trailing 12 months, in millions of $, except employees| Company | Market Cap | Revenues |
|---|---|---|
 Rayzebio Inc |
962.34 | - |
 Bristol myers Squibb Company |
128,928.40 | 50,033.00 |
 Regeneron Pharmaceuticals Inc |
96,735.94 | 16,896.20 |
 Madrigal Pharmaceuticals Inc |
13,113.46 | 1,427.94 |
 Nuvalent Inc |
9,751.98 | 4.23 |
 Prometheus Biosciences Inc |
9,488.45 | 4.00 |
| SUBTOTAL | 318,217.17 | 73,570.38 |
74 more competitors available
Sign in to see all competitors of Rayzebio Inc .
Sources: see Methodology: Peer & Competitor Identification, Sourcing.
Updated on:
Focus of this report: publicly traded companies. Ten additional tables on Rayzebio Inc versus competitors, including market share analysis, are in the navigation menu under Competition. To download the tables, please subscribe.
Rayzebio Inc's Competitors Named by the Company
Competitive relationships identified from Rayzebio Inc reports and corroborating sources, each with a basis and confidence.| Competitor | Basis | Confidence |
|---|---|---|
| Actinium Pharmaceuticals Inc | Company report | 85% |
| Agentix Corp | Company report | 85% |
| Cadrenal Therapeutics Inc | Company report | 85% |
| Monopar Therapeutics Inc | Company report | 85% |
| Spyre Therapeutics Inc | Company report | 85% |
| Qsam Biosciences Inc | Company report | 85% |
| Shattuck Labs Inc | Company report | 85% |
| Protagonist Therapeutics inc | Company report | 85% |
| Adaptimmune Therapeutics Plc | Company report | 85% |
| AbbVie Inc. | Company report | 85% |
| AstraZeneca plc | Company report | 85% |
| Amgen, Inc. | Company report | 85% |
| Briacell Therapeutics Corp | Company report | 85% |
| Fate Therapeutics Inc | Company report | 85% |
| Sana Biotechnology Inc | Company report | 85% |
| Sellas Life Sciences Group Inc | Company report | 85% |
| Can fite Biopharma Ltd | Company report | 85% |
| Elicio Therapeutics Inc | Company report | 85% |
| Intra cellular Therapies Inc | Company report | 85% |
| Nuvalent Inc | Company report | 85% |
| Cell Source Inc | Company report | 85% |
| Vincerx Pharma Inc | Company report | 85% |
| Allogene Therapeutics Inc | Company report | 85% |
| Pfizer Inc. | Company report | 85% |
| Johnson and Johnson | Company report | 85% |
| Takeda Pharmaceutical Company Limited | Company report | 85% |
| Gilead Sciences, Inc. | Company report | 85% |
| Sanofi S.A. | Company report | 85% |
| Gsk Plc | Company report | 85% |
| Marker Therapeutics inc | Company report | 85% |
| Fusion Pharmaceuticals Inc | Company report | 85% |
| Eli Lilly and Company | Company report | 85% |
| Merck and Co Inc | Company report | 85% |
| Corvus Pharmaceuticals, Inc. | Company report | 85% |
| Cue Biopharma Inc | Company report | 85% |
| Adicet Bio Inc | Company report | 85% |
| Tempest Therapeutics Inc | Company report | 85% |
| Janux Therapeutics Inc | Company report | 85% |
| BGNE | Company report | 85% |
| Compass Therapeutics Inc | Company report | 85% |
| Mosaic Immunoengineering Inc | Company report | 85% |
| Cytokinetics Incorporated | Company report | 85% |
| Edgewise Therapeutics inc | Company report | 85% |
| Voyager Therapeutics Inc | Company report | 85% |
| Nuvation Bio Inc | Company report | 85% |
| MNMD | Company report | 85% |
| Calidi Biotherapeutics Inc | Company report | 85% |
| Arcellx Inc | Company report | 85% |
| Allarity Therapeutics Inc | Company report | 85% |
| Fulgent Genetics Inc | Company report | 85% |
| Cabaletta Bio Inc | Company report | 85% |
| Coherus Oncology inc | Company report | 85% |
| Beone Medicines Ltd | Company report | 85% |
| Atlantic Coastal Acquisition Corp Ii | Company report | 85% |
| Sunshine Biopharma Inc | Company report | 85% |
| Definium Therapeutics Inc | Company report | 85% |
| Silexion Therapeutics Corp | Company report | 85% |
| Redwoods Acquisition Corp | Company report | 85% |
| Tradeup Acquisition Corp | Company report | 85% |
| Alx Oncology Holdings Inc | Company report | 85% |
| Kura Oncology Inc | Company report | 85% |
| Candel Therapeutics Inc | Company report | 85% |
| Scinai Immunotherapeutics Ltd | Company report | 85% |
| Bright Minds Biosciences Inc | Company report | 85% |
| Sonnet Biotherapeutics Holdings Inc | Company report | 85% |
| Agios Pharmaceuticals Inc | Company report | 85% |
| Iovance Biotherapeutics inc | Company report | 85% |
| Pliant Therapeutics Inc | Company report | 85% |
| Igm Biosciences Inc | Company report | 85% |
| Kiromic Biopharma Inc | Company report | 85% |
| Tc Biopharm holdings Plc | Company report | 85% |
| Greenwich Lifesciences Inc | Company report | 85% |
| Clearside Biomedical Inc | Company report | 85% |
| Neximmune Inc | Company report | 85% |
| United Health Products Inc | Company report | 85% |
| Macrogenics Inc | Company report | 85% |
| Akero Therapeutics Inc | Company report | 85% |
| Exscientia Plc | Company report | 85% |
| Sagimet Biosciences inc | Company report | 85% |
| Eisai Co., Ltd. | Company report | 85% |
| Atreca inc | Company report | 85% |
| Lineage Cell Therapeutics Inc | Company report | 85% |
| Seagen Inc | Company report | 85% |
| Surrozen Inc | Company report | 85% |
| Ngm Biopharmaceuticals Inc | Company report | 85% |
| Corbus Pharmaceuticals Holdings Inc | Company report | 85% |
| Tango Therapeutics, Inc. | Company report | 85% |
| Immunome Inc | Company report | 85% |
| Oncosec Medical Incorporated | Company report | 85% |
| Exelixis, Inc. | Company report | 85% |
| Nextcure Inc | Company report | 85% |
| Morphic Holding inc | Company report | 85% |
| Rafael Holdings Inc | Company report | 85% |
| Legend Biotech Corporation | Company report | 85% |
| Carisma Therapeutics Inc | Company report | 85% |
| Cytodyn inc | Company report | 85% |
| Replimune Group Inc | Company report | 85% |
| BMS | Company report | 85% |
| Arena Pharmaceuticals Inc | Company report | 85% |
| Gracell Biotechnologies Inc | Company report | 85% |
| Lunai Bioworks Inc | Company report | 85% |
| Boehringer Ingelheim AG | Company report | 85% |
| RENB | Company report | 85% |
| Bayer-Schering Pharmaceutical | Company report | 85% |
| Exagen Inc | Company report | 85% |
| Astellas Pharma Inc. | Company report | 85% |
| Autolus Therapeutics Plc | Company report | 85% |
| Syndax, Inc. | Company report | 85% |
| Nurix Therapeutics Inc | Company report | 85% |
| Mirum Pharmaceuticals Inc | Company report | 85% |
| Celularity Inc | Company report | 85% |
| APDN | Company report | 85% |
| Alzamend Neuro Inc | Company report | 85% |
| Urogen Pharma Ltd | Company report | 85% |
| Perspective Therapeutics Inc | Company report | 85% |
| Incannex Healthcare Inc | Company report | 85% |
| Black Diamond Therapeutics Inc | Company report | 85% |
| Anaptysbio Inc | Company report | 85% |
| Vyne Therapeutics Inc | Company report | 85% |
| Editas Medicine Inc | Company report | 85% |
| Moonlake Immunotherapeutics | Company report | 85% |
| Springworks Therapeutics Inc | Company report | 85% |
| Immix Biopharma Inc | Company report | 85% |
| Medicines Co | Company report | 85% |
| Bellicum Pharmaceuticals Inc | Company report | 85% |
| Sage Therapeutics Inc | Company report | 85% |
| Bridgebio Pharma Inc | Company report | 85% |
| Adc Therapeutics Sa | Company report | 85% |
| Vertex Pharmaceuticals Inc | Company report | 85% |
| Biogen Inc | Company report | 85% |
| Fortress Biotech Inc | Company report | 85% |
| Nkarta Inc | Company report | 85% |
| Novartis Ag | Company report | 85% |
| Ideaya Biosciences Inc | Company report | 85% |
| Aldeyra Therapeutics Inc | Company report | 85% |
| Cogent Biosciences Inc | Company report | 85% |
| Prelude Therapeutics Inc | Company report | 85% |
| Esperion Therapeutics Inc | Company report | 85% |
| Horizon Therapeutics Public Limited Company | Company report | 85% |
| Tiziana Life Sciences Ltd | Company report | 85% |
| Incyte Corporation | Company report | 85% |
| Alkermes Plc | Company report | 85% |
| Abbott Laboratories | Company report | 85% |
| Galapagos Nv | Company report | 85% |
| Ovid Therapeutics Inc | Company report | 85% |
| Repare Therapeutics Inc | Company report | 85% |
| Aclaris Therapeutics Inc | Company report | 85% |
| Xilio Therapeutics Inc | Company report | 85% |
| Regeneron Pharmaceuticals Inc | Company report | 85% |
| Deciphera Pharmaceuticals Inc | Company report | 85% |
| Kiniksa Pharmaceuticals International Plc | Company report | 85% |
| Alnylam Pharmaceuticals Inc | Company report | 85% |
| Nektar Therapeutics | Company report | 85% |
| Bluebird Bio Inc | Company report | 85% |
| Prothena Corporation Public Limited Company | Company report | 85% |
| Viatris Inc | Company report | 85% |
| Celldex Therapeutics inc | Company report | 85% |
| Travere Therapeutics Inc | Company report | 85% |
| Jazz Pharmaceuticals Plc | Company report | 85% |
| Reunion Neuroscience Inc | Company report | 85% |
| Blueprint Medicines Corporation | Company report | 85% |
| Humanigen Inc | Company report | 85% |
| Lexicon Pharmaceuticals Inc | Company report | 85% |
| Puma Biotechnology Inc | Company report | 85% |
| Merus N v | Company report | 85% |
| Prometheus Biosciences Inc | Company report | 85% |
| Bausch Health Companies Inc | Company report | 85% |
| Affimed N v | Company report | 85% |
| Xencor Inc | Company report | 85% |
| Alexion Pharmaceuticals Inc | Company report | 85% |
| Axsome Therapeutics Inc | Company report | 85% |
| Atara Biotherapeutics Inc | Company report | 85% |
| Biomarin Pharmaceutical Inc | Company report | 85% |
| Arcus Biosciences Inc | Company report | 85% |
| Teva Pharmaceutical Industries Limited | Company report | 85% |
| Harpoon Therapeutics Inc | Company report | 85% |
| United Therapeutics Corporation | Company report | 85% |
| Longboard Pharmaceuticals Inc | Company report | 85% |
| Cerevel Therapeutics Holdings Inc | Company report | 85% |
Competitor Evidence Detail
Company report basis, confidence, active dates and source counts for Rayzebio Inc's named competitors require a Commercial License.
Methodology: see Methodology: Peer & Competitor Identification, Sourcing.
Rayzebio Inc's Business Segment Mix vs Peers
Revenue by operating segment or division, as named and reported by each company. Segment names are the filer's own and are not standardized across companies. Do not assume a same-named or similarly-named segment is defined identically between two companies. Shares are of each company's own total revenue and are not required to sum to 100% (intersegment revenue, unallocated items).| Company | Largest Segment |
|---|---|
| Madrigal Pharmaceuticals Inc | Reportable 100.00 % |
| Rhythm Pharmaceuticals Inc | Single Reportable 100.00 % |
| Immunome Inc | Single reportable segment 100.00 % |
| Supernus Pharmaceuticals inc | Reportable 100.00 % |
| Novavax inc | Reportable 100.00 % |
Source: operating segment revenue as reported in each company's reports (10-K/10-Q), via the CSIMarket API, leaf-level reportable segments only (parent roll-up segments are excluded where sub-segments are separately disclosed).
Rayzebio Inc's Productivity vs Peers Comparison
Revenue and income per employee, trailing 12 months, in $; market cap in millions of $| Company | Market Cap | Revenue / Employee | Income / Employee |
|---|---|---|---|
| Rayzebio Inc | 962 | - | - |
| Bristol myers Squibb Company | 128,928 | 1,539,477 | 284,338 |
| Regeneron Pharmaceuticals Inc | 96,736 | 1,096,444 | 312,615 |
| Madrigal Pharmaceuticals Inc | 13,113 | 1,560,590 | -169,905 |
| Nuvalent Inc | 9,752 | 18,566 | -1,974,009 |
| Prometheus Biosciences Inc | 9,488 | 27,937 | -1,052,881 |
| PEERS TOTAL | 317,255 | 1,216,542 | 139,654 |
Rayzebio Inc's Geographic Revenue Exposure vs Peers
Revenue by country/region as reported in each company's most recent report. Disclosure granularity varies by filer (some report by country, others by broad region) and is shown as disclosed.| Company | Largest Market |
|---|---|
| Bristol myers Squibb Company | United States 69.43 % |
| Novavax inc | United States 68.88 % |
| Opko Health Inc | IE 27.07 % |
| Xoma Royalty Corporation | CH 54.36 % |
| Adc Therapeutics Sa | United States 96.73 % |
Source: revenue geography as reported in each company's reports (10-K/10-Q), via the CSIMarket API. Percentages are of that company's own total consolidated revenue for its most recent reported period.
Rayzebio Inc's SWOT
Every point below is a fixed rule applied to a metric already shown elsewhere on this page (Market Structure, Profitability, Valuation, Run-Rate, Stock Performance, Quality Breadth) not an independent strategic assessment. A blank quadrant means no rule was met, not that none apply.Strengths
No rule matched.
Weaknesses
- Piotroski F-Score of 2 or below, the standard financial-distress signal.
Opportunities
- A meaningful share of competitors (57.10 %) show financial-distress signals, a possible opening to gain share.
Threats
- Tracked peer group's revenue run-rate is broadly decelerating (-15.6% annualized).
Methodology: see Methodology: SWOT Analysis.
Rayzebio Inc's Financial Strength vs Peers Comparison
Quick ratio, working capital, debt to equity and asset turnover, trailing 12 months| Company | Quick Ratio | Working Capital | Debt / Equity |
|---|---|---|---|
| Rayzebio Inc | - | - | - |
| Bristol myers Squibb Company | 0.48 | 1.44 | 2.12 |
| Regeneron Pharmaceuticals Inc | 0.58 | 3.56 | 0.06 |
| Madrigal Pharmaceuticals Inc | 0.83 | 3.39 | 0.60 |
| Nuvalent Inc | 1.98 | 13.90 | - |
| Prometheus Biosciences Inc | 7.04 | 23.30 | - |
Quick ratio = cash / current liabilities; working capital ratio = current assets / current liabilities; asset turnover = revenue / total assets. Peers in the Blank Checks industry are excluded.
Rayzebio Inc's Revenue and Income Growth vs Peers
Quarterly revenue and net income growth, year over year and quarter over quarter| Company | Period | Revenue Y/Y | Income Y/Y |
|---|---|---|---|
| Rayzebio Inc | Q3 2023 | - | - |
| Bristol myers Squibb Company | Q3 2026 | +6.9 % | -1.5 % |
| Regeneron Pharmaceuticals Inc | Q3 2026 | +36.3 % | +33.5 % |
| Madrigal Pharmaceuticals Inc | Q3 2026 | +50.1 % | - |
| Nuvalent Inc | Q1 2026 | - | - |
| Prometheus Biosciences Inc | Q1 2023 | -71.8 % | - |
| PEERS TOTAL | +17.5 % | +84.3 % |
Growth is shown only where both periods are positive. Peers in the Blank Checks industry are excluded.
Rayzebio Inc's Peers' Costs of Sales and Capital Expenditures
Context for revenue growth: peer costs and capex, year over year and quarter over quarter| Company | Period | Costs Y/Y | Capex Y/Y |
|---|---|---|---|
| Rayzebio Inc | Q3 2023 | - | - |
| Bristol myers Squibb Company | Q3 2026 | +20.7 % | +7.5 % |
| Regeneron Pharmaceuticals Inc | Q3 2026 | +104.1 % | +49.1 % |
| Madrigal Pharmaceuticals Inc | Q3 2026 | - | +1.8 % |
| Nuvalent Inc | Q1 2026 | - | - |
| Prometheus Biosciences Inc | Q1 2023 | - | - |
Rayzebio Inc's Returns and Turnover vs Peers
ROA, ROI and ROE (trailing 12 months), receivables and inventory turnover| Company | ROA | ROI | ROE |
|---|---|---|---|
| Rayzebio Inc | - | - | - |
| Bristol myers Squibb Company | 10.47% | 13.59% | 43.83% |
| Regeneron Pharmaceuticals Inc | 11.50% | 13.00% | 15.07% |
| Madrigal Pharmaceuticals Inc | - | - | - |
| Nuvalent Inc | - | - | - |
| Prometheus Biosciences Inc | - | - | - |
ROA = net income / total assets; ROI = net income / investments; ROE = net income / equity; turnover ratios use trailing 12 month revenue (receivables) and cost of sales (inventory).
Rayzebio Inc's Valuation vs Peers
P/E, price to sales, PEG, price to cash flow and price to book| Company | P/E | Price / Sales |
|---|---|---|
| Rayzebio Inc | - | - |
| Bristol myers Squibb Company | 13.92 | 2.58 |
| Regeneron Pharmaceuticals Inc | 20.26 | 5.73 |
| Madrigal Pharmaceuticals Inc | - | 9.18 |
| Nuvalent Inc | - | 2,303.80 |
| Prometheus Biosciences Inc | - | 2,375.08 |
| PEERS AVERAGE | 37.68 | 4.33 |
P/E = price / diluted EPS (trailing 12 months); PEG = P/E divided by EPS growth; the average row divides the peers' combined market cap by their combined income, sales, cash flow and equity.